Rationale and design of ePPOP-ID: a multicenter randomized controlled trial using an electronic-personalized program for obesity in pregnancy to improve delivery.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
07 Oct 2020
Historique:
received: 18 02 2020
accepted: 27 09 2020
entrez: 8 10 2020
pubmed: 9 10 2020
medline: 18 5 2021
Statut: epublish

Résumé

Pre-pregnancy obesity and excessive gestational weight gain (GWG) are established risk factors for adverse pregnancy, delivery and birth outcomes. Pregnancy is an ideal moment for nutritional interventions in order to establish healthier lifestyle behaviors in women at high risk of obstetric and neonatal complications. Electronic-Personalized Program for Obesity during Pregnancy to Improve Delivery (ePPOP-ID) is an open multicenter randomized controlled trial which will assess the efficacy of an e-health web-based platform offering a personalized lifestyle program to obese pregnant women in order to reduce the rate of labor procedures and delivery interventions in comparison to standard care. A total of 860 eligible pregnant women will be recruited in 18 centers in France between 12 and 22 weeks of gestation, randomized into the intervention or the control arm and followed until 10 weeks of postpartum. The intervention is based on nutrition, eating behavior, physical activity, motivation and well-being advices in which personalization is central, as well as the use of a mobile/tablet application. Inputs includes data from the medical record of participants (medical history, anthropometric data), from the web platform (questionnaires on dietary habits, eating behavior, physical activity and motivation in both groups), and adherence to the program (time of connection for the intervention group only). Data are collected at inclusion, 32 weeks, delivery and 10 weeks postpartum. As primary outcome, we will use a composite endpoint score of obstetrical interventions during labor and delivery, defined as caesarean section and instrumental delivery (forceps and vacuum extractor). Secondary outcomes will consist of data routinely collected as part of usual antenatal and perinatal care, such as GWG, hypertension, preeclampsia, as well as fetal and neonatal outcomes including premature birth, gestational age at birth, birth weight, macrosomia, Apgar score, arterial umbilical cord pH, neonatal traumatism, hyperbilirubinemia, respiratory distress syndrome, transfer in neonatal intensive care unit, and neonatal adiposity. Post-natal outcomes will be duration of breastfeeding, maternal weight retention and child weight at postnatal visit. The findings of the ePPOP-ID trial will help design e-health intervention program for obese women in pregnancy. ClinicalTrials.gov Identifier: NCT02924636 / October 5th 2016.

Sections du résumé

BACKGROUND BACKGROUND
Pre-pregnancy obesity and excessive gestational weight gain (GWG) are established risk factors for adverse pregnancy, delivery and birth outcomes. Pregnancy is an ideal moment for nutritional interventions in order to establish healthier lifestyle behaviors in women at high risk of obstetric and neonatal complications.
METHODS METHODS
Electronic-Personalized Program for Obesity during Pregnancy to Improve Delivery (ePPOP-ID) is an open multicenter randomized controlled trial which will assess the efficacy of an e-health web-based platform offering a personalized lifestyle program to obese pregnant women in order to reduce the rate of labor procedures and delivery interventions in comparison to standard care. A total of 860 eligible pregnant women will be recruited in 18 centers in France between 12 and 22 weeks of gestation, randomized into the intervention or the control arm and followed until 10 weeks of postpartum. The intervention is based on nutrition, eating behavior, physical activity, motivation and well-being advices in which personalization is central, as well as the use of a mobile/tablet application. Inputs includes data from the medical record of participants (medical history, anthropometric data), from the web platform (questionnaires on dietary habits, eating behavior, physical activity and motivation in both groups), and adherence to the program (time of connection for the intervention group only). Data are collected at inclusion, 32 weeks, delivery and 10 weeks postpartum. As primary outcome, we will use a composite endpoint score of obstetrical interventions during labor and delivery, defined as caesarean section and instrumental delivery (forceps and vacuum extractor). Secondary outcomes will consist of data routinely collected as part of usual antenatal and perinatal care, such as GWG, hypertension, preeclampsia, as well as fetal and neonatal outcomes including premature birth, gestational age at birth, birth weight, macrosomia, Apgar score, arterial umbilical cord pH, neonatal traumatism, hyperbilirubinemia, respiratory distress syndrome, transfer in neonatal intensive care unit, and neonatal adiposity. Post-natal outcomes will be duration of breastfeeding, maternal weight retention and child weight at postnatal visit.
DISCUSSION CONCLUSIONS
The findings of the ePPOP-ID trial will help design e-health intervention program for obese women in pregnancy.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov Identifier: NCT02924636 / October 5th 2016.

Identifiants

pubmed: 33028261
doi: 10.1186/s12884-020-03288-x
pii: 10.1186/s12884-020-03288-x
pmc: PMC7542973
doi:

Banques de données

ClinicalTrials.gov
['NCT02924636']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

602

Subventions

Organisme : Ministère de la Santé et des Services sociaux
ID : 590780193

Références

J Psychosom Res. 1985;29(1):71-83
pubmed: 3981480
BMC Public Health. 2018 Oct 05;18(1):1160
pubmed: 30290793
BJOG. 2010 Oct;117(11):1316-26
pubmed: 20353459
Curr Opin Obstet Gynecol. 2009 Dec;21(6):521-6
pubmed: 19809317
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
J Clin Psychol. 2011 Feb;67(2):143-54
pubmed: 21157930
J Clin Endocrinol Metab. 2008 Dec;93(12):4774-9
pubmed: 18826999
Gynecol Obstet Fertil. 2011 Feb;39(2):100-5
pubmed: 21317009
BMC Pregnancy Childbirth. 2011 Mar 24;11:23
pubmed: 21435246
Obstet Gynecol. 2005 Dec;106(6):1349-56
pubmed: 16319262
Obes Rev. 2011 Jul;12(7):e602-20
pubmed: 21521451
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005270
pubmed: 15846748
J Med Internet Res. 2014 May 13;16(5):e128
pubmed: 24824164
Obstet Gynecol. 2011 Dec;118(6):1395-401
pubmed: 22105270
Acta Obstet Gynecol Scand. 2012 May;91(5):538-45
pubmed: 22229625
Am J Prev Med. 2009 Sep;37(3):173-80
pubmed: 19595557
PLoS One. 2012;7(6):e38818
pubmed: 22701717
Am J Obstet Gynecol. 2010 Jun;202(6):574.e1-8
pubmed: 20132923
BMJ. 2012 May 16;344:e2088
pubmed: 22596383
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004095
pubmed: 15846698
BMC Med. 2014 Oct 13;12:161
pubmed: 25315237
BMC Med. 2012 May 10;10:47
pubmed: 22574949
Health Psychol Rev. 2015;9(3):323-44
pubmed: 25104107
Scand J Public Health. 2007;35(1):95-103
pubmed: 17366093
BMC Pregnancy Childbirth. 2011 Oct 26;11:81
pubmed: 22029725
Public Health Nutr. 2014 Sep;17(9):1939-48
pubmed: 24477188
Circulation. 2013 Jan 15;127(2):260-7
pubmed: 23212719
Am J Clin Nutr. 2010 May;91(5):1336-41
pubmed: 20237138
Patient Educ Couns. 2014 Nov;97(2):256-60
pubmed: 25153313

Auteurs

Philippe Deruelle (P)

Univ. Lille, CHU Lille, EA 4489 - Environnement Périnatal et Santé, F-59000, Lille, France. pderuelle@unistra.fr.
Pôle Gynécologie, Obstétrique et Fertilité, Hôpitaux Universitaires de Strasbourg, 67200, Strasbourg cedex, France. pderuelle@unistra.fr.

Sophie Lelorain (S)

Univ. Lille, CNRS, CHU Lille, UMR 9193 - SCALab - Cognitive and Affective Sciences, Lille, France.

Sylvie Deghilage (S)

Univ. Lille, CHU Lille, EA 4489 - Environnement Périnatal et Santé, F-59000, Lille, France.

Emmanuelle Couturier (E)

Univ. Lille, CHU Lille, EA 4489 - Environnement Périnatal et Santé, F-59000, Lille, France.

Elodie Guilbert (E)

Univ. Lille, CHU Lille, EA 4489 - Environnement Périnatal et Santé, F-59000, Lille, France.

Paul Berveiller (P)

Department of Obstetrics and Gynecology, Poissy Saint Germain hospital, Poissy, France.

Marie Victoire Sénat (MV)

Assistance Publique-Hôpitaux de Paris, Department of Gynecology-Obstetrics, Bicêtre Hospital, University of Paris-Sud, University of Medicine Paris- Saclay Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France.

Christophe Vayssière (C)

Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, Toulouse, France.

Loïc Sentilhes (L)

Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France.

Franck Perrotin (F)

Department of Gynecology and Obstetrics, Inserm U1253 « Imaging and Brain » (iBrain). CHU Bretonneau, Tours, France.

Denis Gallot (D)

Pôle Femme Et Enfant, CHU Estaing, Clermont-Ferrand cedex 1, France.
R2D2-EA7281, Université d'Auvergne, Faculté de Médecine, Place Henri Dunant, Clermont-Ferrand, France.

Céline Chauleur (C)

INSERM, SAINBIOSE, U1059, Dysfonction Vasculaire et Hémostase, Université Jean-Monnet, CIC1408, F- 42055, Saint-Etienne, France.

Nicolas Sananes (N)

Pôle Gynécologie, Obstétrique et Fertilité, Hôpitaux Universitaires de Strasbourg, 67200, Strasbourg cedex, France.
Maternal Fetal Medicine Department, INSERM 1121 "Biomaterials and Bioengineering", Strasbourg University Hospital, Strasbourg, France.

Emmanuel Roth (E)

Pôle Gynécologie, Obstétrique et Fertilité, Hôpitaux Universitaires de Strasbourg, 67200, Strasbourg cedex, France.

Dominique Luton (D)

Department of Obstetrics and Gynecology, AP-HP, Bichat hospital, Paris, France.

Marie Caputo (M)

Department of Obstetrics and Gynecology, Lens general hospital, Lens, France.

Elodie Lorio (E)

Department of Obstetrics and Gynecology, Valenciennes general hospital, Valenciennes, France.

Carla Chatelet (C)

Department of Obstetrics and Gynecology, Béthune general hospital, Béthune, France.

Julien Couster (J)

Department of Obstetrics and Gynecology, Boulogne general hospital, Boulogne, France.

Oumar Timbely (O)

Department of Obstetrics and Gynecology, Meaux general hospital, Meaux, France.

Muriel Doret-Dion (M)

Department of obstetrics and gynecology surgery, Femme mere enfant university hospital, hospices civils de Lyon, Bron, France.

Alain Duhamel (A)

Univ. Lille, CHU Lille, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000, Lille, France.

Marie Pigeyre (M)

Department of medicine, endocrinology division, Mc Master university, Hamilton, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH